{"entity":{"id":"paper-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"GEOMETRY mono-1: capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","aka":[],"tldr":"The MET inhibitor capmatinib shrank tumours in two thirds of untreated and four in ten previously treated patients with MET exon 14-skipping lung cancer, leading to the first approval for this driver, while MET-amplified tumours responded only at very high copy number.","summary":"Phase 2 multicohort study of 364 patients with advanced non-small-cell lung cancer with MET exon 14 skipping or MET amplification treated with capmatinib.\n\nIn exon 14-skipping disease, objective response was 68 percent in treatment-naive and 41 percent in previously treated patients, with median durations of 12.6 and 9.7 months; in MET-amplified disease, response was 40 percent only with gene copy number of 10 or more. Peripheral oedema and nausea were common.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2020","url":"https://doi.org/10.1056/NEJMoa2002787"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32877583/"}],"tags":[],"related":[],"cancers":["met-altered-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["capmatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["geometry-mono-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2020,"doi":"10.1056/NEJMoa2002787","pmid":"32877583","authors":"Wolf J, Seto T, Han JY, et al.","paperType":"observational","findings":["Exon 14 skipping: objective response 68 percent (treatment-naive) and 41 percent (previously treated).","MET amplification: response 40 percent at gene copy number 10 or more, low below that."],"whatItMeans":"MET exon 14 skipping is a standard target in lung cancer, tested by RNA-based methods, with capmatinib or tepotinib as first-line or later options.","caveats":["Single-arm; peripheral oedema is frequent and can be dose limiting.","MET amplification without exon 14 skipping is a weaker target."],"changedPractice":true,"participants":364},"route":"/key-papers/paper-geometry-mono-1-capmatinib-nejm-2020/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"}],"drug":[{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/"}],"trial":[{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}